MiNK Therapeutics Strikes Convertible Note Deal with Agenus
Company Announcements

MiNK Therapeutics Strikes Convertible Note Deal with Agenus

MiNK Therapeutics (INKT) has released an update.

MiNK Therapeutics, Inc. has secured a financial agreement with Agenus Inc., involving a convertible promissory note worth up to $5.0 million. This arrangement allows MiNK Therapeutics to access funds as needed, subject to Agenus’s approval, at an annual interest rate of 2%. The note is repayable on demand after January 1, 2026, and can be settled in cash or equity in the event of a qualified financing event. This move could signal a strategic growth phase for MiNK Therapeutics, potentially piquing the interest of investors monitoring the biotech sector.

For further insights into INKT stock, check out TipRanks’ Stock Analysis page.

Related Articles
Carrie WilliamsINKT Upcoming Earnings Report: What to Expect?
TheFlyMiNK Therapeutics presents data on iNKT cell therapy programs
TipRanks Auto-Generated NewsdeskMiNK Therapeutics Appoints Dr. Robert Kadlec to Board
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App